Safety and Tolerability of Medications for ADHD

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Attention defi cit hyperactivity disorder (ADHD) is a common neurobehavioral disorder in children and adolescents that comprises core symptoms of developmentally inappropriate levels of inattention and/or hyperactivity and impulsivity. Current drug treatment approaches for ADHD comprise stimulant medications (methylphenidate, amphetamines) and non-stimulant medications (atomoxetine, clonidine and guanfacine). Drugs for ADHD appear to be safe and well tolerated, and most of the adverse events observed in randomised clinical trials were mild and temporary. Stimulants and atomoxetine are associated with decreased appetite and gastrointestinal pain. An increased risk of insomnia exists for stimulants, while atomoxetine and alpha-2 agonists are associated with somnolence. Long-term safety is poorly evaluated. Concerns regarding cardiovascular and psychiatric adverse events have been raised by regulatory authorities in the last decade. However, there is currently no proven association between ADHD medications and an increased risk of these events, and their incidence is extremely low.

Original languageEnglish
Title of host publicationPharmacovigilance in Psychiatry
PublisherSpringer International Publishing
Pages233-251
Number of pages19
ISBN (Electronic)9783319247410
ISBN (Print)9783319247397
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Safety
Guanfacine
Amphetamines
Methylphenidate
Impulsive Behavior
Sleep Initiation and Maintenance Disorders
Clonidine
Appetite
Pharmaceutical Preparations
Psychiatry
Randomized Controlled Trials
Pain
Incidence
Atomoxetine Hydrochloride
Therapeutics

Keywords

  • Amphetamines
  • Atomoxetine
  • Attention deficit hyperactivity disorder
  • Methylphenidate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Clavenna, A., & Bonati, M. (2016). Safety and Tolerability of Medications for ADHD. In Pharmacovigilance in Psychiatry (pp. 233-251). Springer International Publishing. https://doi.org/10.1007/978-3-319-24741-0

Safety and Tolerability of Medications for ADHD. / Clavenna, Antonio; Bonati, Maurizio.

Pharmacovigilance in Psychiatry. Springer International Publishing, 2016. p. 233-251.

Research output: Chapter in Book/Report/Conference proceedingChapter

Clavenna, A & Bonati, M 2016, Safety and Tolerability of Medications for ADHD. in Pharmacovigilance in Psychiatry. Springer International Publishing, pp. 233-251. https://doi.org/10.1007/978-3-319-24741-0
Clavenna A, Bonati M. Safety and Tolerability of Medications for ADHD. In Pharmacovigilance in Psychiatry. Springer International Publishing. 2016. p. 233-251 https://doi.org/10.1007/978-3-319-24741-0
Clavenna, Antonio ; Bonati, Maurizio. / Safety and Tolerability of Medications for ADHD. Pharmacovigilance in Psychiatry. Springer International Publishing, 2016. pp. 233-251
@inbook{1d71c735907d43268393268e333e7ef6,
title = "Safety and Tolerability of Medications for ADHD",
abstract = "Attention defi cit hyperactivity disorder (ADHD) is a common neurobehavioral disorder in children and adolescents that comprises core symptoms of developmentally inappropriate levels of inattention and/or hyperactivity and impulsivity. Current drug treatment approaches for ADHD comprise stimulant medications (methylphenidate, amphetamines) and non-stimulant medications (atomoxetine, clonidine and guanfacine). Drugs for ADHD appear to be safe and well tolerated, and most of the adverse events observed in randomised clinical trials were mild and temporary. Stimulants and atomoxetine are associated with decreased appetite and gastrointestinal pain. An increased risk of insomnia exists for stimulants, while atomoxetine and alpha-2 agonists are associated with somnolence. Long-term safety is poorly evaluated. Concerns regarding cardiovascular and psychiatric adverse events have been raised by regulatory authorities in the last decade. However, there is currently no proven association between ADHD medications and an increased risk of these events, and their incidence is extremely low.",
keywords = "Amphetamines, Atomoxetine, Attention deficit hyperactivity disorder, Methylphenidate",
author = "Antonio Clavenna and Maurizio Bonati",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-24741-0",
language = "English",
isbn = "9783319247397",
pages = "233--251",
booktitle = "Pharmacovigilance in Psychiatry",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Safety and Tolerability of Medications for ADHD

AU - Clavenna, Antonio

AU - Bonati, Maurizio

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Attention defi cit hyperactivity disorder (ADHD) is a common neurobehavioral disorder in children and adolescents that comprises core symptoms of developmentally inappropriate levels of inattention and/or hyperactivity and impulsivity. Current drug treatment approaches for ADHD comprise stimulant medications (methylphenidate, amphetamines) and non-stimulant medications (atomoxetine, clonidine and guanfacine). Drugs for ADHD appear to be safe and well tolerated, and most of the adverse events observed in randomised clinical trials were mild and temporary. Stimulants and atomoxetine are associated with decreased appetite and gastrointestinal pain. An increased risk of insomnia exists for stimulants, while atomoxetine and alpha-2 agonists are associated with somnolence. Long-term safety is poorly evaluated. Concerns regarding cardiovascular and psychiatric adverse events have been raised by regulatory authorities in the last decade. However, there is currently no proven association between ADHD medications and an increased risk of these events, and their incidence is extremely low.

AB - Attention defi cit hyperactivity disorder (ADHD) is a common neurobehavioral disorder in children and adolescents that comprises core symptoms of developmentally inappropriate levels of inattention and/or hyperactivity and impulsivity. Current drug treatment approaches for ADHD comprise stimulant medications (methylphenidate, amphetamines) and non-stimulant medications (atomoxetine, clonidine and guanfacine). Drugs for ADHD appear to be safe and well tolerated, and most of the adverse events observed in randomised clinical trials were mild and temporary. Stimulants and atomoxetine are associated with decreased appetite and gastrointestinal pain. An increased risk of insomnia exists for stimulants, while atomoxetine and alpha-2 agonists are associated with somnolence. Long-term safety is poorly evaluated. Concerns regarding cardiovascular and psychiatric adverse events have been raised by regulatory authorities in the last decade. However, there is currently no proven association between ADHD medications and an increased risk of these events, and their incidence is extremely low.

KW - Amphetamines

KW - Atomoxetine

KW - Attention deficit hyperactivity disorder

KW - Methylphenidate

UR - http://www.scopus.com/inward/record.url?scp=84989231103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989231103&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-24741-0

DO - 10.1007/978-3-319-24741-0

M3 - Chapter

SN - 9783319247397

SP - 233

EP - 251

BT - Pharmacovigilance in Psychiatry

PB - Springer International Publishing

ER -